Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON‐2 Study
Asia-Pacific Journal of Clinical Oncology · 2026-06 · 22 (3) · 447-456
DOI: 10.1111/ajco.70041 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, online erschienen am 04.11.2025. Verfasst von Atsuko Kakihara und 29 weiteren Autor:innen. Beteiligte Einrichtung: Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Leucovorin, Fluorouracil, Irinotecan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Aim
Nanoliposomal irinotecan plus fluorouracil and folinic acid (NFF) has been used as a standard treatment for unresectable pancreatic cancer refractory to gemcitabine‐based therapies. However, reports on the efficacy of NFF in older patients with pancreatic cancer, especially in those aged > 75 years, are limited. We retrospectively compared the efficacy and safety of NFF in older and younger patients.
Methods
We reviewed the clinical records of 161 consecutive patients with unresectable pancreatic cancer who were treated with NFF between June 2020 and May 2021. Patients ≥ 75 years old were classified as the older group. We compared the antitumor efficacy, safety, and survival of the older and younger groups. Geriatric nutritional risk index (GNRI) was used as a prognostic indicator in the older group.
Results
Overall, 26 and 135 patients were enrolled in the older and younger groups, respectively. The pretreatment characteristics of the two groups were not significantly different. Median overall survival and progression‐free survival were 10.9 and 5.0 months, respectively, in the older group, versus 7.6 ( p = 0.15) and 3.1 months ( p = 0.29), respectively, in the younger group. There were no clinical differences in the adverse events or the overall response rates between the two groups. The older group with GNRI < 86 tended to have a shorter overall survival.
Conclusion
Older patients with pancreatic cancer may benefit from NFF to the same extent as younger patients without severe adverse events. GNRI needs further study as a predictor of NFF efficacy in older patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Digestive and Lifestyle Diseases, Department of Human and Environmental Sciences, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima-shi, Kagoshima, Japan.
- Department of Medical Oncology, Kagoshima City Hospital, Kagoshima-shi, Kagoshima, Japan.
- Department of Gastroenterology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki-shi, Nagasaki, Japan.
- Clinical Research Institute, National Kyushu Cancer Center, Fukuoka-shi, Fukuoka, Japan.
- Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Ube-shi, Yamaguchi, Japan.
- Department of Internal Medicine, Minato Medical Clinic, Fukuoka-shi, Fukuoka, Japan.
Zitieren
APA
Kakihara, A., Takeshita, S., Shimokawa, M., Otsuka, T., Arima, S., Ido, A., Shibuki, T., Nakazawa, J., Miwa, K., Koga, F., Ueda, Y., Kubotsu, Y., Shimokawa, H., Komori, A., Nishikawa, K., Otsu, S., Hosokawa, A., Sakai, T., Oda, H., …, & Mitsugi, K. (2026). Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON‐2 Study. Asia-Pacific Journal of Clinical Oncology, 22(3), 447-456. https://doi.org/10.1111/ajco.70041
Vancouver
Kakihara A, Takeshita S, Shimokawa M, Otsuka T, Arima S, Ido A, et al. Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON‐2 Study. Asia-Pacific Journal of Clinical Oncology. 2026;22(3):447-456. doi:10.1111/ajco.70041
BibTeX
@article{Kakihara2026,
author = {Kakihara, Atsuko and Takeshita, Shigeyuki and Shimokawa, Mototsugu and Otsuka, Taiga and Arima, Shiho and Ido, Akio and Shibuki, Taro and Nakazawa, Junichi and Miwa, Keisuke and Koga, Futa and Ueda, Yujiro and Kubotsu, Yoshihito and Shimokawa, Hozumi and Komori, Azusa and Nishikawa, Kazuo and Otsu, Satoshi and Hosokawa, Ayumu and Sakai, Tatsunori and Oda, Hisanobu and Kawahira, Machiko and Arita, Shuji and Honda, Takuya and Tsuneyoshi, Kengo and Taguchi, Hiroki and Kawaguchi, Yasunori and Fujita, Toshihiro and Sakae, Takahiro and Shirakawa, Tsuyoshi and Mizuta, Toshihiko and Mitsugi, Kenji},
title = {Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Older Versus Younger Patients With Unresectable Pancreatic Cancer: The Multicenter NAPOLEON‐2 Study},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
volume = {22},
number = {3},
pages = {447--456},
doi = {10.1111/ajco.70041}
}
EUVIMED